LOG IN
SIGN UP
MARKET
LPCN
LPCN
Lipocine Inc
NASDAQ
4.600
-0.140
-2.96%
Opening 11:46 05/30 EDT
OPEN
4.680
PREV CLOSE
4.740
HIGH
4.790
LOW
4.600
VOLUME
8.18K
TURNOVER
27.66K
52 WEEK HIGH
16.15
52 WEEK LOW
3.300
MARKET CAP
23.95M
P/E (TTM)
-2.1573
1D
5D
1M
3M
1Y
5Y
Watching Lipocine; Zacks Small-Cap Research Sets $40 Price Valuation Says We Model All Of Lipocine's Assets To Eventually Be Developed By Partners And Lipocine To Receive Upfronts, Milestones And Royalties
Benzinga · 05/19 17:01
Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression
Seeking Alpha · 05/16 13:47
Lipocine Says Pilot Study of LPCN 1154 for Postpartum Depression Shows 'Positive' Topline Results
Lipocine Says Pilot Study of LPCN 1154 for Postpartum Depression Shows 'Positive' Topline Results
MT Newswires · 05/16 11:13
BRIEF-Positive Topline Clinical Results Support Streamlined Development Pathway For LPCN 1154
Reuters · 05/16 11:10
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression
PR Newswire · 05/16 11:00
Lipocine Inc: Current report
Press release · 05/16 07:03
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 05/11 17:46
BRIEF-Lipocine Inc says On May 10 Board Of Directors Approved A Reverse Stock Split Ratio Of 1-For-17
Reuters · 05/11 17:03
About LPCN
Lipocine Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging its Lip’ral platform to develop differentiated products through oral delivery. It has a portfolio of differentiated product candidates that target high unmet needs for neurological and psychiatric Central Nervous System (CNS) disorders, liver diseases, and hormone supplementation for men and women. The Company's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its clinical development pipeline candidates include LPCN 1154 for postpartum depression (PPD), LPCN 2101 for epilepsy, and LPCN 1148 an androgen therapy for the management of cirrhosis. The Company is focused on exploring partnering opportunities for LPCN 1107, its candidate for the prevention of preterm birth; LPCN 1148, for the management of decompensated cirrhosis; LPCN 1144, its candidate for the treatment of non-cirrhotic NASH, and LPCN 1111.
Webull offers kinds of Lipocine Inc stock information, including NASDAQ:LPCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPCN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading LPCN stock methods without spending real money on the virtual paper trading platform.